SORIANO V, VALER L, GONZALEZ DE REQUENA D, DE MENDOZA C, GONZALEZ-LAHOZ J; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. H-1999.

Instituto de Salud Carlos III, Madrid, Spain.

BACKGROUND: The impact of drug levels, resistance, and inhibitory quotients, on the response to a SQV/rit-based salvage therapy was examined. METHODS: Patients exposed to multiple PI (no SQV) and on current virologic failure were recruited in a multicenter trial in Spain. All initiated SQV 1000 mg bid/rit 100 mg bid. A significant viral response was considered when VL drops >1 log and/or to <50 cop/ml were attained. RESULTS: A total of 139 patients were analyzed. Median time on prior PI was 28 months. Mean VL before beginning SQV/rit was 4.3 logs and mean CD4 count was 350 cells/micro-l. A total of 54 patients discontinued tx before completing 1 year (22 lost of follow-up, 14 voluntary withdrawal, 15 due to toxicities). At 1 year, VL drops >1 log occurred in 69.4% of patients on treatment (ITT, 42.4%). Moreover, 65.3% had <50 cop/ml. In the univariate analysis, viral response was higher in subjects with >0.1 ug/ml and 0.1 microg/ml and < 4 SQV mutations were independently associated with response (OR=4.8 and R=7.8, respectively). CONCLUSIONS: A significant viral response at 1 year on a SQV/rit based salvage regimen occurs in more than two thirds of patients. Drug levels seems to be the main predictor of response at weeks 12 (early response), since it split patients with or without good tx adherence. At week 24 (intermediate response), the impact of HIV genotyping is the highest, suggesting that viral response in those taking the drugs is highly dependent of resistance. Finally, at week 48 (late response) the impact of the GIQ is the highest, suggesting that both SQV levels and resistance mutations influence in complementary ways the long-term efficacy of therapy.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Anti-HIV Agents
• CD4 Lymphocyte Count
• HIV
• HIV Antibodies
• HIV Infections
• HIV Protease
• HIV Protease Inhibitors
• HIV Seropositivity
• Humans
• Ritonavir
• Salvage Therapy
• Saquinavir
• Spain

Other ID:

• GWAIDS0024916

UI: 102264540

From Meeting Abstracts